With a background in chemical engineering and biochemistry, Christopher I. Halliday counsels clients on strategic intellectual property (IP) issues in pharmaceutical, biotechnology, chemical, medical devices, and food science areas. Christopher prepares and prosecutes patent applications related to new chemical entities, pharmaceutical formulations, and biologics as well as implantable medical devices, chemical processes, and catalysts. Clients turn to Christopher for IP litigation advice and to develop opinions involving infringement, validity, and freedom to operate.
Clients also request Christopher’s assistance in the course of mergers or acquisitions, and negotiating licenses, transfer agreements, and assignments.
Before joining Morgan Lewis, Christopher was employed by a Philadelphia-area IP boutique law firm as an associate. He has also worked at SmithKlineBeecham Pharmaceuticals (now GlaxoSmithKline), the New Hampshire Office of the Attorney General, and the New Hampshire Office of the Public Defender. Christopher has represented many indigent clients in the New Hampshire courts.
Before entering private practice, Christopher worked for corporate, nonprofit, and government organizations.
PTC Therapeutics, Inc. in its acquisition of Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of a clinical-stage investigational therapy for orphan metabolic diseases
Antares Pharma, Inc. in its agreement with Pfizer to develop a combination drug device overdose rescue pen under which Pfizer will develop and commercialize the product in the United States and Antares will receive royalties on net sales
Antares Pharma, Inc. in its agreement with Idorsia Pharmaceuticals for the development of a novel drug device combination product to be developed for the treatment of suspected acute myocardial infarction
Merck in its up to $5.76 billion strategic collaboration with Eisai Co. Ltd. for the worldwide co-development and co-commercialization of Eisai's Lenvima (lenvatinib mesylate)
SQZ Biotechnologies in its $1.37B-plus deal with Roche for a new approach to immuno-oncology where Roche is putting up $125 million for an upfront and near-term milestones in a collaboration deal embedded with $1 billion in development milestones and another $250 million for each new therapy that manages to receive approval. Roche and SQZ will jointly develop anticancer cell therapies that trigger antitumor responses with cell therapies that can target antigens that are beyond the reach of other cell-based adoptive immunity strategies
Eli Lilly in its agreement with NextCure, Inc. for the discovery and development of immuno-oncology therapies to discover novel cancer targets utilizing NextCure's proprietary FIND-IO platform. Under the terms of the agreement, Lilly and NextCure will each receive options to exclusively license antibodies resulting from the collaboration
Nevakar Inc. in its $50 million product financing agreement with an affiliate of NovaQuest Capital Management, for the continued development of five differentiated, sterile injectable products
Regeneron in its up to $1 billion agreement with Alnylam Pharmaceuticals for the development and commercialization of new RNA interference therapeutics for diseases in the eye, central nervous system and liver. As part of the transaction, Regeneron made a $400 million investment in Alnylam equity
Acerta Pharma B.V. in implementation of IP program and in its acquisition by AstraZeneca
Many small, midsize, and multinational companies in the life sciences, technology, and financial services sector in establishing and implementing their intellectual property
OncoEthix SA in implementation of IP program and in its acquisition by Merck
Foresight Biotherapeutics, Inc. in implementation of an IP program, and acquisition of Foresight by Shire
Tabula Rasa HealthCare, Inc. in connection with its $60 million initial public offering
A medical device company in litigation in the Western District of Washington resulting in favorable settlement
University of Delaware in developing and attending its Proof of Concept program
Temple University, Beasley School of Law, 2002, LL.M. (Trial Advocacy)
Franklin Pierce Law Center, 1999, J.D. and LL.M. (IP)
Pennsylvania State University, 1996, B.S., Chemical Engineering
Pennsylvania State University, 1996, B.S., Biochemistry
US Patent and Trademark Office
Awards and Affiliations
Member, Engineering Advisory Committee Board for Penn State University, 2017-Current
Member, Practice Group of the Year, Intellectual Property, Law360 (2019)
Member, Litigation Department of the Year–Intellectual Property, The American Lawyer (2019)